Evidence supporting the use of: Coenzyme Q10 (CoQ10)
For the health condition: Apathy

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Coenzyme Q10 (CoQ10) has some scientific evidence suggesting a potential benefit in treating apathy, especially in specific clinical contexts such as Parkinson’s disease. Apathy is a common neuropsychiatric symptom characterized by a lack of motivation, and is frequently observed in neurodegenerative disorders. CoQ10 is a mitochondrial cofactor with antioxidant properties, and mitochondrial dysfunction has been implicated in the pathogenesis of neurodegenerative diseases and their associated symptoms, including apathy.

One notable study is a randomized controlled trial published in 2014, which investigated the effects of high-dose CoQ10 in patients with Parkinson’s disease. The study found that CoQ10 supplementation was associated with improved scores on the Apathy Scale compared to placebo. The proposed mechanism is linked to CoQ10’s role in enhancing mitochondrial function and reducing oxidative stress, which may influence neuronal circuits involved in motivation and reward. However, the evidence is limited to specific populations—primarily those with neurodegenerative diseases—and is not robustly supported in the general population or for primary psychiatric apathy.

Overall, while there is some scientific basis for the use of CoQ10 in reducing apathy in neurodegenerative conditions, the strength and generalizability of the evidence are limited. More large-scale, well-designed studies are necessary to confirm these preliminary findings and to establish standardized dosing and patient selection criteria.

More about coenzyme Q10 (CoQ10)
More about Apathy